Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1984
Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized studyM Valdivieso, M A Burgess, M S Ewer, et al.Cancer|January 1, 1989
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinomaG N Hortobagyi, D Frye, A U Buzdar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasiaP Anderlini, R S Benjamin, F C Wong, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGsA Naing, H Veasey-Rodrigues, D S Hong, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancerS M Swain, F S Whaley, M C Gerber, et al.ESMO Open|January 21, 2023
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trialE de Azambuja, E Agostinetto, M Procter, et al.Pageof 4